



Yukon Immunization Program Manual

Section 3 - Immunization Schedules



SECTION 3 – IMMUNIZATION SCHEDULES

Table of Contents

Vaccine Abbreviations and Vaccines.....	1
1.0 GUIDELINES FOR IMMUNIZATION SCHEDULES.....	2
1.1 CONSIDERATION OF IMMUNIZATION HISTORY.....	3
1.2 CONSIDERATIONS FOR CLIENTS INITIATING OR RESUMING IMMUNIZATION AT 7 YEARS OF AGE AND OLDER.....	3
2.0 ROUTINE SCHEDULES.....	4
2.1 SCHEDULE A: BASIC IMMUNIZATION FOR CHILDREN STARTING SERIES AT 2 MONTHS OF AGE.....	4
2.2 SCHEDULE B: CHILDREN 1 TO 6 YEARS OF AGE (INCLUSIVE) WHEN STARTING OR RESUMING IMMUNIZATION.....	6
2.3 SCHEDULE C: CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE (INCLUSIVE) WHEN STARTING OR RESUMING IMMUNIZATION.....	7
<i>Personalized Schedule Worksheet for Children and Adolescents, Aged 7-17 Years (inclusive)</i>	8
2.4 SCHEDULE D: ADULTS AGE 18 AND OLDER WHEN STARTING OR RESUMING IMMUNIZATION.....	9
<i>Personalized Schedule Worksheet for Adults 18 Years of Age or Older</i>	11
2.5 SCHEDULE E: IMMUNIZATION FOR ADULTS WHO HAVE COMPLETED A PRIMARY SERIES OF CHILDHOOD VACCINES.....	12
2.6 SCHEDULE F: COVID-19 IMMUNIZATION.....	14
3.0 MINIMUM INTERVALS BETWEEN VACCINE DOSES.....	17
3.1 MINIMUM INTERVALS BETWEEN VACCINE DOSES.....	18
4.0 TIMING AND SPACING OF BIOLOGICAL PRODUCTS.....	20
4.1 TIMING AND SPACING OF INACTIVATED VACCINES.....	20
4.2 TIMING AND SPACING OF LIVE ATTENUATED VACCINES.....	21
4.3 SPACING OF VACCINES AND ANTIBODY-CONTAINING PRODUCTS.....	22
4.4 SPACING OF VACCINES AND BLOOD DONATION.....	23
4.5 VACCINATION FOLLOWING VACCINATION ADMINISTRATION ERRORS.....	23
4.5.1 Vaccine or Antigen Given at Less Than the Minimum Interval.....	23
4.5.2 Vaccine Given at Less Than the Minimum Age.....	23
4.5.3 Live Vaccines Given Less Than 4 Weeks Apart.....	23
4.5.4 Expired Vaccine.....	24
4.6 Tuberculin Testing.....	24
5.0 REFERENCES.....	25

Vaccine Abbreviations and Vaccines

The table below provides a list of the abbreviations used in this section and the vaccines to which they refer. For information on specific vaccines and their use see [Section 8-Biological Products](#).

Abbreviation	Vaccine
DTaP-HB-IPV-Hib	Diphtheria and tetanus toxoids, acellular pertussis, hepatitis B, inactivated polio and <i>Haemophilus influenzae</i> type b vaccine
DTaP-IPV-Hib	Diphtheria and tetanus toxoids, acellular pertussis, inactivated polio and <i>Haemophilus influenzae</i> type b vaccine
DTaP-IPV	Diphtheria and tetanus toxoids, acellular pertussis, and inactivated polio vaccine
HA	Hepatitis A vaccine
HB	Hepatitis B vaccine--available on its own or in combination format as DTaP-HB-IPV-Hib as INFANRIX hexa®.
Hib	<i>Haemophilus influenzae</i> type b vaccine--available on its own or in combination as DTaP-HB-IPV-Hib or DTaP-IPV-Hib vaccines
HPV4	Human papillomavirus vaccine(quadrivalent, HPV types 6, 11, 16, and 18)
HPV9	Human papillomavirus vaccine (nonavalent, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58)
Flu	Influenza vaccine
IPV	Inactivated polio vaccine. Available on its own or in combination format as DTaP-HB-IPV-Hib, DTaP-IPV-Hib, DTaP-IPV, Td/IPV or Tdap-IPV vaccines
Men-C-C	Meningococcal serogroup C conjugate vaccine
Men-C-ACYW-135	Meningococcal quadrivalent conjugate vaccines (serogroups A, C, Y, W-135)
MMR	Measles, mumps and rubella vaccine
MMRV	Measles, mumps, rubella and varicella vaccine
PCV7	Pneumococcal conjugate vaccine, 7-valent vaccine
PCV13	Pneumococcal conjugate vaccine,13-valent vaccine
PPV23	Pneumococcal polysaccharide vaccine, 23-valent
Rota	Rotavirus vaccine, monovalent (ROTARIX®) or pentavalent (RotaTeq®)
Td	Tetanus and diphtheria toxoids vaccine
Tdap	Tetanus and diphtheria toxoids and acellular pertussis vaccine
Tdap-IPV	Tetanus and diphtheria toxoids, acellular pertussis and inactivated polio vaccine
Td/IPV	Tetanus and diphtheria toxoids, and inactivated polio vaccine
Var	Varicella vaccine
Zos	Zoster Varicella

1.0 GUIDELINES FOR IMMUNIZATION SCHEDULES

Optimal response to a vaccine depends on many factors, including the nature of the vaccine and the age and immune status of the recipient.

Adhere as closely as possible to recommended vaccine schedules. Recommendations for the age at which vaccines are administered are influenced by age-specific risks for disease, age-specific risks for complications, ability of persons of a certain age to respond to the vaccine, and in infancy, potential interference with the immune response by passively transferred maternal antibody.

Recommended ages and intervals between doses of vaccines and toxoids provide optimal protection or have the best evidence of efficacy. Recommended ages and intervals may differ from those contained in the product monographs and are based on research and expert opinion.

For premature infants, chronological age based on actual birth date should be used as opposed to corrected age. There is no minimum weight for commencing immunization.

Use each client contact as an opportunity to review immunization status and administer all vaccines for which the client is eligible. Clients should also be informed of the availability of other vaccines that are recommended by the National Advisory Committee on Immunization but are not currently publicly funded.

Determine vaccine eligibility by assessing the client's:

- Age
- Health status and underlying medical conditions
- Lifestyle or occupational risk factors
- Contact with individuals at risk of vaccine preventable disease
- Local disease epidemiology.

In general, individuals who missed being immunized on the routine schedule remain eligible for indicated vaccines and these should be offered at opportune encounters with an immunization service provider. In some instances, these vaccines will no longer be indicated beyond a certain age. In other instances, the individual remains eligible for the vaccine, however the recommended product may change depending on the individual's age. See [Section 8-Biological Products](#) for vaccine eligibility and recommended product/schedule.

The number of doses required to complete a series may be reduced for some vaccines as children age out of infancy or early childhood. When an individual presents, assess any previously received doses against the schedule for their current age and complete the series according to the schedule appropriate for their age.

Interruption of a recommended series does not require starting the series over again, regardless of the interval elapsed (with the exception of oral typhoid vaccine). A longer than recommended interval between vaccine doses does not reduce final antibody concentrations, although protection might not be attained until the recommended number of doses has been administered.

By contrast, doses given at less than the minimum interval or minimum age may result in less than optimal antibody response and should generally not be counted as part of the series.

The full recommended vaccine dose volume should be administered. The recommended dosages of biological products are derived from clinical trials and post-marketing research. Administration of amounts smaller than those recommended and administration of divided doses such as half doses given over two visits is likely to result in inadequate protection. If a partial dose has been given it should be considered invalid and a full dose given subsequently.

Exceeding the recommended dosage volume is not necessary to achieve protection and may result in an increase in adverse events, especially local reactions, due to excessive concentrations of antigens. Certain vaccines (e.g., Td) produce increased rates of local or systemic reactions in some recipients when administered too frequently. Such reactions may be the result of the formation of antigen-antibody complexes and are not allergic reactions.

1.1 CONSIDERATION OF IMMUNIZATION HISTORY

A verbal history of immunization is not considered proof of immunity. When a client presents without written documentation of immunization, a thorough assessment of the reliability of the verbal immunization history as well as risk factors for vaccine preventable diseases should be undertaken. At minimum, a verbal history should include date (day/month/year) and sufficient information to identify the product administered (i.e., the generic name or product name). If the provider determines that the history is unreliable or the risk of disease acquisition is assessed to be high, the client should be considered unimmunized and should be offered immunization according to the schedule for their current age. Written documentation may include that recorded in the Child Health Passport, on the ImmunizeCA app, or other client-held records. A verbal history of a vaccine preventable disease is generally not sufficient proof of immunity against that disease but varies by disease and by age.

1.2 CONSIDERATIONS FOR CLIENTS INITIATING OR RESUMING IMMUNIZATION AT 7 YEARS OF AGE AND OLDER

When developing a schedule for an unimmunized or incompletely immunized client, it is important to consider several factors including age at presentation, health status, lifestyle or occupational risk factors, local epidemiology of vaccine preventable diseases, and for children, future opportunities to participate in school based immunization programs (grades 6 and 9). Since each situation is different, the client may be best served by developing a personalized schedule. The recommendations in subsections 2.3 and 2.4 (schedules C and D) will guide the development of the schedule for routine immunization of children, adolescents and adults, and should be used in combination with the relevant Biological Product pages (see [Section 8-Biological Products](#) and [Table 3.1 Minimum Intervals Between Vaccine Doses](#)). For guidance in developing schedules for medically fragile clients and other special populations, see [Section 5-Immunization of Special Populations](#).

2.0 ROUTINE SCHEDULES

2.1 SCHEDULE A: BASIC IMMUNIZATION FOR CHILDREN STARTING SERIES AT 2 MONTHS OF AGE

The following recommendations will guide the development of the schedule for healthy children and adolescents, and should be used in combination with the relevant Biological Product pages (see [Section 8- Biological Products](#)). Children with specific health conditions and/or risk factors should be immunized according to principles outlined in [Section 5 -Immunization of Special Populations](#). Refer to the [Children's Immunization Schedule](#) for children who are up to date.

AGE	VACCINE
2 months	DTaP-HB-IPV-Hib (or DTaP-IPV-Hib and HB) ❶ PCV13 Men-C-C ❷ Rota ❸
4 months	DTaP-HB-IPV-Hib (or DTaP-IPV-Hib and HB) PCV13 Men-C-C (high risk infants only) ❷ Rota ❸
6 months	DTaP-HB-IPV-Hib (or DTaP-IPV-Hib and HB) PCV13 (high risk infants only) Men-C-C (depending on product for 2-3 dose series) ❹ Rota ❸ (RotaTeq® is a 3 dose series) Flu ❸
On or after the 1 st birthday	MMR Var Men-C-C PCV13
18 months	DTaP-IPV-Hib
School Entry (4-6 years of age)	Tdap-IPV (or DTaP-IPV) ❹ Var MMR (if 2nd dose not received previously)
Grade 6	HPV (2 doses 6 months apart)
Grade 9	Men C-ACYW-135 ❷ Tdap ❸
COVID-19	Refer to Schedule F: COVID-19 Immunization Schedule

- ❶ The primary series of 3 doses of DTaP-containing vaccine should be completed with the same product
- ❷ For **high risk infants**, Men-C-ACYW-135 (Menveo) should be given in place of Men-C-C and administered at 2, 4 and 12 months of age
- ❸ RotaTeq® vaccine, first dose to be given by 14 weeks + 6 days of age. Last dose of 3 dose series by 8 months of age; minimum intervals of 4 weeks. First dose of ROTARIX® vaccine to be given no later than 20 weeks less 1 day of age. Second dose to be administered by 8 months less 1 day of age.
- ❹ Menjugate® is a 3 dose series for children under 12 months of age, NeisVac C® is a two dose series.

- ⑤ Yearly influenza immunization is recommended (i.e., two doses in the first year of vaccine receipt and one dose in subsequent years).
- ⑥ School entry booster may be given as QUADRACEL® or ADACEL-POLIO® or PEDIACEL®. This dose is not necessary when the fourth dose of a diphtheria/tetanus/pertussis-containing vaccine has been given after the 4th birthday.
- ⑦ As of school year 2016-2017, Meningococcal Quadrivalent Conjugate (Men C-ACYW-135) vaccine offered in grade 9 school program.
- ⑧ Children who have had a tetanus, diphtheria, and pertussis combined vaccine (Tdap) at 10 years of age or older do not require an additional dose of Tdap in grade 9.

2.2 SCHEDULE B: CHILDREN 1 TO 6 YEARS OF AGE (INCLUSIVE) WHEN STARTING OR RESUMING IMMUNIZATION

Timing of visits and need for specific vaccines will require adjustment based on the age at which the child starts the schedule. The following recommendations will guide the development of the schedule for healthy children and adolescents, and should be used in combination with the relevant Biological Product pages (see [Section 8-Biological Products](#)). Children with specific health conditions and/or risk factors should be immunized according to principles outlined in [Section 5-Immunization of Special Populations](#).

VISIT	VACCINE
Initial Visit	DTaP-HB-IPV-Hib- or (DTaP-IPV-Hib and HB) ❶ MMR PCV13 ❷ Var (if susceptible) ❸ Men-C-C ❹ Influenza ❺
2 nd (4 weeks after 1st visit)	DTaP-HB-IPV-Hib- or (DTaP-IPV-Hib and HB) ❶
3 rd (8 weeks after 1 st PCV13)	PCV13
4 th (16 weeks after 1st visit AND at least 8 weeks after 2nd dose of HB)	DTaP-HB-IPV-Hib- or (DTaP-IPV-Hib and HB) ❶
5 th (6 months after 3rd dose of DTaP-containing vaccine)	DTap-IPV-Hib or (DTaP-IPV) ❻
School Entry (4-6 years of age)	Tdap-IPV or (DTaP-IPV) ❼ MMRV
Grade 6	HPV (2 doses given 6 months apart)
Grade 9	Men C-ACYW-135 ❸ Tdap ❾
COVID-19	Refer to Schedule F: COVID-19 Immunization Schedule

- ❶ The primary series of 3 doses of DTaP-containing vaccine should be completed with the same product. If child is unable to complete the primary series before the 7th birthday, separate DTaP-IPV-Hib and HB vaccines to be used.
- ❷ Refer to [Section 8, Biological Products](#), Completing a Pneumococcal Conjugate Vaccine Series. High risk children should receive a dose of PPV23 at 2 years of age or older, and at least 8 weeks after their final dose of PCV13.
- ❸ As of June 2018, a varicella susceptible person is one without a history of lab confirmed varicella or herpes zoster after 12 months of age and without a history of age appropriate varicella immunization. Individuals with a documented exemption in the immunization registry prior to this date due to previous disease will be considered immune. A self-reported history of varicella or physician diagnosed varicella is adequate only if disease occurred before 2004.
- ❹ For high risk children, Men-C-ACYW-135 should be given in place of Men-C-C and administered according to age at presentation (see Section 8, Meningococcal Quadrivalent Conjugate Vaccines).
- ❺ Yearly influenza immunization is recommended (i.e., for children less than 9 years of age: two doses, 4 weeks apart, for initial year of vaccine receipt and one dose in subsequent years).
- ❻ If the child has completed an age-appropriate series of Hib AND over 4 years of age can give Tdap-IPV.
- ❼ This dose is not necessary when the fourth dose of a diphtheria/tetanus/pertussis/polio -containing vaccine has been given after the 4th birthday.
- ❸ As of school year 2016-2017, Meningococcal Quadrivalent Conjugate (Men C-ACYW-135) vaccine offered in grade 9 school program.
- ❾ Children who have had a tetanus, diphtheria, and pertussis combined vaccine (Tdap) at 10 years of age or older do not require an additional dose of Tdap in grade 9.

2.3 SCHEDULE C: CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE (INCLUSIVE) WHEN STARTING OR RESUMING IMMUNIZATION

The following recommendations will guide the development of the schedule for healthy children and adolescents, and should be used in combination with the relevant Biological Product pages (see [Section 8-Biological Products](#)). Children and adolescents with specific health conditions and/or risk factors should be immunized according to principles outlined in: [Section 5 immunization of Special Populations](#).

VACCINE	SCHEDULING GUIDELINES
HB	<ul style="list-style-type: none"> Children 11-15 years of age (inclusive): 2 doses (1.0 mL each) given at 0 and 6 months. Children under 11 years of age and adolescents aged 16 and 17 years: 3 doses (0.5 ML each) given at 0, 1, and 6 months
HPV9	<ul style="list-style-type: none"> Children in grade 6 and eligible individuals 9-14 years of age (inclusive): 2 doses given at 0 and 6 months. Eligible individuals initiating vaccine series at 15 to 17 years of age (inclusive): 3 doses given at 0, 2 and 6 months.
Men-C-C	<ul style="list-style-type: none"> Children unimmunized after 1 year of age are eligible for one dose.
Men-C-ACYW-135	<ul style="list-style-type: none"> Eligible for one dose in grade 9 only.
MMR	<ul style="list-style-type: none"> 2 doses given at least 4 weeks apart (second dose may be given as MMRV 12 weeks after first doses in those eligible for varicella vaccine if under 13 years of age).
Tdap or Tdap-IPV (if polio vaccine is also required)	<ul style="list-style-type: none"> 3 doses given at: 0 and 1 month, followed by a 3rd dose 6-12 months after the 2nd dose. For children resuming immunization, if the first dose of DTaP-containing vaccine was administered before the 1st birthday, administer additional dose(s) in order to complete a 4-dose primary series. (See Section 8 Biological Products). If the series is completed before the 10th birthday, give a booster in grade 9.
Var	<ul style="list-style-type: none"> As of June 2018, a varicella susceptible person is one without a history of lab confirmed varicella or herpes zoster after 12 months of age and without a history of age appropriate varicella immunization. Individuals with a documented exemption in the immunization registry prior to this date due to previous disease will be considered immune. A self-reported history of varicella or physician diagnosed varicella is adequate only if disease occurred before 2004. Susceptible children under 13 years of age: 2 doses given 12 weeks apart (may be given as MMRV in those also eligible for MMR vaccine, up to age 12). Susceptible adolescents 13 years of age and older: give 2 doses of varicella vaccine 6 weeks apart.
COVID-19	Refer to Schedule F: COVID-19 Immunization Schedule

Personalized Schedule Worksheet for Children and Adolescents, Aged 7-17 Years (inclusive)

The following worksheet may assist the immunizer to develop an appropriate schedule for the client.

Client's Name _____

Date of Birth _____

Personal Health Number _____

	1 st visit	2 nd visit	3 rd visit	4 th visit	5 th visit
Date					
COVID-19					
HB					
HPV9					
Men-C-C					
Men-C-ACYW-135					
MMR					
MMRV					
Tdap					
Tdap-IPV					
Var					

2.4 SCHEDULE D: ADULTS AGE 18 AND OLDER WHEN STARTING OR RESUMING IMMUNIZATION

The following vaccines are routinely offered to eligible adults in Yukon; this schedule should be used in combination with the relevant Biological Product pages (see [Section 8 Biological Products](#)). Additional vaccines may be recommended due to risk factors i.e., occupation, travel, lifestyle, health status. Refer to [Section 5-Immunization of Special Populations](#).

VACCINE	SCHEDULING GUIDELINES AND ROUTINE ELIGIBILITY CRITERIA
COVID-19	<ul style="list-style-type: none"> Refer to Schedule F: COVID-19 Immunization Schedule
HB	<ul style="list-style-type: none"> Individuals 18 and 19 years of age: 3 doses (0.5 mL each) given at 0, 1 and 6 months Individuals 20 years of age and older born in 1980 or later: 3 doses (1.0 mL each) given at 0, 1, and 6 months
HPV9	<ul style="list-style-type: none"> Females and Males 18 years of age up to and including age 26: 3 doses given at 0, 2 and 6 months. Females and Males 27 years age and older: same schedule, not provided free
Men-C-C	<ul style="list-style-type: none"> Adults up to 24 years of age (inclusive): 1 dose (for unimmunized clients)
MMR	<ul style="list-style-type: none"> Measles Protection: up to 2 doses of MMR are recommended for all individuals born on or after January 1, 1970 (1957 for health care workers) who do not have a history of lab confirmed measles infection, lab evidence of immunity, or documentation of 2 doses of a live measles-containing vaccine at 12 months of age or older and given at least 4 weeks apart. Mumps Protection: up to 2 doses of MMR are recommended for all individuals born on or after January 1, 1970 (1957 for health care workers) who do not have a history of lab confirmed mumps infection, or documentation of 2 doses of a live mumps-containing vaccine at 12 months of age and older and given at least 4 weeks apart. Rubella Protection: one dose of MMR is recommended for all individuals born on or after January 1, 1957 who have not received 1 dose of a rubella-containing vaccine or who do not have serologic evidence of rubella immunity. If 2 doses of MMR vaccine are required, give at least 4 weeks apart.
IPV	<ul style="list-style-type: none"> Routine primary immunization against poliomyelitis of adults living in Canada is not considered necessary. Primary immunization with polio vaccine is recommended only for unimmunized adults who are at higher risk of exposure to wild polioviruses: refer to Section 8, Polio Vaccine. 3 doses given at: 0 and 1 month, followed by a 3rd dose 6-12 months after the 2nd dose. If IPV is indicated, for those also requiring protection against tetanus, diphtheria or pertussis, combination products can be used (i.e., Tdap-IPV).
Td/Tdap	<ul style="list-style-type: none"> Adults receiving a primary immunization series should receive one dose of Tdap (to provide protection against pertussis) followed by 2 doses of Td. This series should be given at: 0 and 1 month, followed by a 3rd dose 6-12 months after the 2nd dose. For adults resuming an interrupted immunization series, provide additional doses of vaccine to ensure that the client has received at least 3 doses of a diphtheria and tetanus containing vaccine with at least one dose after the 4th birthday. Adults without a Tdap booster are eligible for one dose of Tdap.

Var	<ul style="list-style-type: none"> • As of June 2018, a varicella susceptible person is one without a history of lab confirmed varicella or herpes zoster after 12 months of age and without a history of age appropriate varicella immunization. Individuals with a documented exemption in the immunization registry prior to this date due to previous disease will be considered immune. A self-reported history of varicella or physician diagnosed varicella is adequate only if disease occurred before 2004. • If susceptible, give 2 doses 6 weeks apart.
Zos	<ul style="list-style-type: none"> • Recommended and provided free to individuals: <ul style="list-style-type: none"> • January 1, 2021 to December 5, 2021: Individuals 65-70 years of age • December 6, 2021 to December 31, 2022: Individuals 65 years of age and older • Starting January 1, 2023, the publicly funded indications will be updated to only include Yukon residents aged 65-79. • 2 doses given 2 to 6 months apart. • Individuals 50-64 years of age, recommended but not provided free

Personalized Schedule Worksheet for Adults 18 Years of Age or Older

The following worksheet may assist the immunizer to develop an appropriate schedule for the client.

Client's Name _____

Date of Birth _____

Personal Health Number _____

	1 st visit	2 nd visit	3 rd visit	4 th visit	5 th visit
Date					
COVID-19					
HB					
HPV9					
Men-C-C					
MMR					
MMRV					
Tdap					
Tdap-IPV					
Var					
Zos					

2.5 SCHEDULE E: IMMUNIZATION FOR ADULTS WHO HAVE COMPLETED A PRIMARY SERIES OF CHILDHOOD VACCINES

For unimmunized adults see 2.4 Schedule D.

The following vaccines are routinely offered to eligible adults in YT; this schedule should be used in combination with the relevant Biological Product pages (see [Section 8-Biological Products](#)). Additional vaccines may be recommended due to risk factors i.e., occupation, travel, lifestyle, health status. Refer to [Section 5-Immunization of Special Populations](#).

Vaccine	Group	Frequency Of Immunization
COVID-19	<ul style="list-style-type: none"> Refer to Schedule F: COVID-19 Immunization Schedule 	
Td or Tdap	<p>Any adult.</p> <p>Adults with a tetanus prone wound.</p>	<ul style="list-style-type: none"> Every 10 years; 1 dose should be given as Tdap if not previously received in adulthood. Refer to Tetanus Prophylaxis in Wound Management.
MMR	All susceptible adults.	<ul style="list-style-type: none"> 1 or 2 doses as needed.
Flu	All individuals	<ul style="list-style-type: none"> Annually
HPV9	<p>Females and Males 18 years of age up to and including age 26.</p> <p>Females and Males 27 years age and older not provided free</p>	<ul style="list-style-type: none"> 3 dose series
PPV23	<p>All individuals 65 years of age and older.</p> <p>Individuals with specific medical conditions. For a complete list of indications refer to Section 8, Biological Products Pneumococcal Polysaccharide Vaccine.</p>	<ul style="list-style-type: none"> One-time dose. Once only revaccination, 5 years after initial dose, as required for specific medical conditions. See Section 8, Biological Products Pneumococcal Polysaccharide Vaccine
Var	<p>As of June 2018, a varicella susceptible person is one without a history of lab confirmed varicella or herpes zoster after 12 months of age and without a history of age appropriate varicella immunization. Individuals with a documented exemption in the immunization registry prior to this date due to previous disease will be considered immune. A self-reported history of varicella or physician diagnosed varicella is adequate only if disease occurred before 2004.</p> <p>For susceptible adults, give 2 doses 6 weeks apart.</p>	<ul style="list-style-type: none"> 1 or 2 doses as needed

Varicella Zoster (Recombinant)	<ul style="list-style-type: none"> • Recommended and provided free to individuals: <ul style="list-style-type: none"> • January 1, 2021 to December 5, 2021: Individuals 65-70 years of age • December 6, 2021 to December 31, 2022: Individuals 65 years of age and older • Starting January 1, 2023, the publicly funded indications will be updated to only include Yukon residents aged 65-79. • Individuals 50-64 years of age, recommended but not provided free 	<ul style="list-style-type: none"> • Two-dose series (lifetime) (2 doses given 2 to 6 months apart)
---------------------------------------	--	--

2.6 SCHEDULE F: COVID-19 IMMUNIZATION

AGES 6 MONTHS – 4 YEARS ①②③④				
Moderna Spikevax BLUE CAP <i>Infant/ Pediatric Presentation 0.1mg/mL</i>	Dose Number	Dose 1	Dose 2	Dose 3 ⑦ <i>(Immunocompromised only)</i>
	Recommended Interval ④⑤	N/A	At least 8 weeks after 1st dose	4-8 weeks after 2nd dose
	Minimum Interval ⑤⑥	N/A	4 weeks	4 weeks
	Dose Amount	0.25mL (25 mcg)	0.25mL (25 mcg)	0.25mL (25 mcg)

AGES 5 TO 11 ①②③④					
Pfizer Cominarty ORANGE CAP <i>Pediatric Presentation 10mcg/ 0.2mL</i>	Dose Number	Dose 1	Dose 2	Dose 3 ⑦ <i>(Immunocompromised only)</i>	Booster #1
	Recommended Interval ④⑤	N/A	8 weeks after 1st dose	28 days after 2nd dose	6 months after completion of primary series
	Minimum Interval ⑤⑥	N/A	19 days after 1st dose	28 days after 2nd dose	5 months after completion of primary series
	Dose Amount	0.2mL (10mcg)	0.2mL (10mcg)	0.2mL (10mcg)	0.2mL (10mcg)

AGES 12 – 17 ③④						
Pfizer Cominarty PURPLE CAP or GREY CAP <i>Adult/ Adolescent Presentation 30mcg/ 0.3mL</i> <i>Preferred product for ages 12- 29</i>	Dose Number	Dose 1	Dose 2	Dose 3 ⑦ <i>(Immunocompromised only)</i>	Booster #1	Booster #2 ⑥ <i>(Immunocompromised only)</i>
	Recommended Interval ④⑤	N/A	8 weeks after 1 st dose	28 days after 2 nd dose	6 months after completion of primary series	6 months after 1 st booster
	Minimum Interval ⑤⑥	N/A	Immunocompetent: 18 days Immunocompromised: 28 days	28 days after 2 nd dose	5 months after completion of primary series	5 months after 1 st booster
	Dose Amount	0.3mL (30 mcg)	0.3mL (30 mcg)	0.3mL (30 mcg)	0.3mL (30 mcg)	0.3mL (30 mcg)

AGES 18 AND OLDER ③④

Pfizer Cominarty PURPLE CAP or GREY CAP <i>Adult/ Adolescent Presentation 30mcg/ 0.3mL</i> <i>Preferred product for ages 12- 29</i>	Dose Number	Dose 1	Dose 2	Dose 3 ⑦ (Immunocompromised only)	Booster #1	Booster #2
	Recommended Interval ④⑤	N/A	8 weeks after 1 st dose	28 days after 2 nd dose	6 months after completion of primary series	6 months after 1 st booster
	Minimum Interval ⑤⑥	N/A	Immunocompetent: 18 days Immunocompromised: 28 days	28 days after 2 nd dose	5 months after completion of primary series	5 months after 1 st booster
	Dose Amount	0.3mL (30 mcg)	0.3mL (30 mcg)	0.3mL (30 mcg)	0.3mL (30 mcg)	0.3mL (30 mcg)

Moderna Spikevax RED CAP <i>50mcg/ 0.25mL</i> <i>Preferred product for ages 30 and older</i>	Dose Number	Dose 1	Dose 2	Dose 3 ⑦ (Immunocompromised only)	Booster #1	Booster #2
	Recommended Interval ④⑤	N/A	8 weeks after 1 st dose	28 days after 2 nd dose	6 months after completion of primary series	6 months after 1 st booster
	Minimum interval ⑤⑥	N/A	Immunocompetent: 21 days Immunocompromised: 28 days	28 days after 2 nd dose	5 months after completion of primary series	5 months after 1 st booster
	Dose Amount	0.5mL (100mcg)	0.5mL (100mcg)	0.5mL (100mcg)	Age 18-69: 0.25mL (50mcg) Age 70+: 0.5mL (100mcg) Immuno-compromised 18+: 0.5mL (100mcg)	Age 18-69: 0.25mL (50mcg) Age 70+: 0.5mL (100mcg) Immuno-compromised 18+: 0.5mL (100mcg)

- ❶ Moderna Spikevax ® Infant/ Pediatric Presentation (0.10mg/mL) is the only COVID-19 vaccine product authorized for use in children 6 months – 4 years of age in the Yukon. For children that are 5 -11 years of age, the use of Pfizer BioNTech Comirnaty (10 mcg) is preferred to Moderna Spikevax (25 mcg). However, Moderna Spikevax (25 mcg) may be offered to children 5 -11 years of age as an alternative to Pfizer-BioNTech Comirnaty (10 mcg).
- ❷ For individuals 5 years of age and older, COVID-19 vaccines may be given concurrently with (i.e., same day), or at any time before or after, non-COVID-19 vaccines (including live and non-live vaccines).
- ❸ The minimum age for vaccine receipt is based on age at presentation.
- ❹ The vaccine series should be completed with the same COVID-19 vaccine product. However, the age appropriate products should be given, and products can be interchanged if needed. See sections on interchangeability.
- ❺ If administration of a dose in the primary series is delayed, the next dose should be provided as soon as possible and the series does not need to be restarted.
- ❻ Reference the product pages in Section 8 for minimum intervals of primary and booster doses, spacing after COVID-19 infection, interchangeability, and all other considerations prior to vaccine administration.
- ❼ **Dose 3 is indicated for moderately to severely immunocompromised individuals.**
 - Active treatment for solid tumour or hematologic malignancies
 - Receipt of solid-organ transplant and taking immunosuppressive therapy
 - Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
 - Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
 - Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome
 - Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (e.g., prednisone equivalent of ≥ 2 mg/kg/day or 20 mg/day if weight > 10 kg, for ≥ 14 days), alkylating agents, antimetabolites, or tumornecrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive (e.g., cancer chemotherapy, radiation therapy, cytotoxic drugs, calcineurin inhibitors, biological response modifiers and antibodies that target lymphocytes).

3.0 MINIMUM INTERVALS BETWEEN VACCINE DOSES

A "minimum interval" is the shortest time between two doses of a vaccine in a multi-dose series in which a protective response to the subsequent dose could be expected. For optimal response, immunizers should observe recommended ages and intervals as much as possible, however, doses given earlier than recommended may still be considered valid and need not be repeated if minimum intervals/ages are observed.

Minimum intervals are primarily relevant in assessing the validity of an immunization series that has already been administered to ensure that there has been sufficient time between doses to generate a protective immune response. Doses given prior to the minimum age or at less than the minimum interval are considered 'invalid' and should generally be repeated. If there is doubt as to whether a dose should be repeated, or whether the dose given too soon can be considered valid, consult with the Vaccine Program Manager.

In certain circumstances, it may be appropriate to administer doses of a multi-dose series at shorter than the routinely recommended intervals.

Consider using minimum intervals if:

1. Protection is required more quickly for an individual at high risk of exposure, e.g., during an outbreak or when traveling overseas.
2. An individual is significantly delayed starting their series and is at high risk of morbidity if exposed.

In these circumstances, minimum intervals may be used for the initial priming doses, however, maintaining the recommended interval to the final dose is generally correlated with higher levels of protective antibody and duration of protection.

[Refer to 3.1 Minimum Intervals Between Vaccine Doses Table](#) for information specific to each vaccine.

3.1 MINIMUM INTERVALS BETWEEN VACCINE DOSES

Vaccine (Dose 1 minimum age)	Minimum Spacing Between Doses (Minimum intervals are typically calculated in weeks)			
	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
DTaP-IPV-Hib (6 weeks)	4 weeks	4 weeks	24 weeks ❶	24 weeks AND minimum age for this dose is 4 years ❷
DTaP-HB-IPV-Hib INFANRIX hexa® (6 weeks)	4 weeks	16 weeks after dose 1 AND 8 weeks after dose 2 AND minimum age for dose 3 is 24 weeks		
Haemophilus Influezae tybe b (Hib) 4 doses (6 weeks) ❸	4 weeks	4 weeks	8 weeks AND minimum age of 12 months	
Hepatitis A (24 weeks)	24 weeks			
Hepatitis B 2 doses Engerix®-B (11 years)	24 weeks			
Hepatitis B 3 doses	4 weeks	16 weeks after dose 1 AND 8 weeks after dose 2 AND minimum age for dose 3 is 24 weeks		
Hepatitis A and B Combined Twinrix®Junior 3 dose (1 year) Twinrix® 3 dose (19 years)	4 weeks	20 weeks		
HPV9 grade 6 program (Gardasil®9) 2 doses (9 years) ❹	24 weeks			
HPV9 (Gardasil®9) 3 doses (9 years)	4 weeks	12 weeks after dose 2 AND 24 weeks after dose 1		
Meningococcal C conjugate NeisVac-C (8 weeks) ❺	8 weeks	8 weeks ❽		
Meningococcal quadrivalent Conjugate Menactra ❿ (2 years)				
Meningococcal quadrivalent Conjugate Menveo ❶❶ (8 weeks)	8 weeks	8 weeks		
MMR (12 months) (6 months) ❶❷	4 weeks			

(continued on next page)

TABLE 3.1 MINIMUM INTERVALS BETWEEN VACCINE DOSES

Vaccine (Dose 1 minimum age)	Minimum Spacing Between Doses (Minimum intervals are typically calculated in weeks)			
	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
MMRV (4 years)	12 weeks			
Pneumococcal conjugate 4 dose(6 weeks) ⁹	4 weeks	4 weeks	8 weeks ¹⁰	
Pneumococcal conjugate 3 dose(8 weeks) ⁹	4 weeks	8 weeks ¹⁰		
Rotavirus (6 weeks) ¹¹	4 weeks	4 weeks		
Td/Tdap(7 years) ¹³	4 weeks	24 weeks		
Varicella Zoster (50 years) ¹⁵	8 weeks			
Varicella (12 months)	12 weeks 6 weeks ¹²			

- ① If DTaP-IPV-Hib 4th dose is given before 12 months of age, another dose of Hib is required, at ≥12 months of age.
- ② Minimum age for dose 5 is 4 years, and is given as Tdap-IPV.
- ③ Based on age of presentation, fewer doses may be recommended (see [Section 8-Biological Products, Haemophilus b conjugate vaccine](#)), with a minimum interval between doses in the primary series of 4 weeks. The booster dose recommended at 18 months of age can be given as early as 12 months of age provided there is an 8-week interval following the previous dose.
- ④ For ages 11-15 years inclusive. Engerix®-B & Recombivax HB® are interchangeable at any dose. In a 2 dose series, if either dose is given as Engerix®-B, there must be a minimum of 24 weeks between doses.
- ⑤ This schedule applies only to those starting a series prior to their 15th birthday. The minimum interval between doses in a 2 dose HPV schedule is 24 weeks. However, if the interval between doses in a 2 dose HPV schedule is shorter than 5 months (150 days), a 3rd dose should be given at least 24 weeks after the 1st dose and 12 weeks after the 2nd dose.
- ⑥ Administer second dose of NeisVac-C vaccine on or after 12 months of age and at least eight weeks after the previous dose.
- ⑦ Depending on product series is 2 – 3 doses, see [Section 8, MCC](#) p.40 for specific schedule
- ⑧ A dose may be given as early as 6 months of age in infants who are travelling to endemic areas or who are identified as contacts of a measles case. If MMR is given before 12 months of age, the child will require two doses of MMR after 12 months of age.
- ⑨ When a series of pneumococcal conjugate vaccine is delayed or interrupted, refer to [Yukon Immunization Program Manual, Section 8. Completing a Pneumococcal Conjugate Vaccine Series](#).
- ⑩ The final dose of pneumococcal conjugate vaccine in a three or four dose series should be given no sooner than 12 months of age, and at least 8 weeks after the previous dose.
- ⑪ The maximum age for RotaTeq® dose 1 is 5 months. The maximum age for last dose of 3 dose series for RotaTeq is 8 months of age.
- ⑫ For those ≤ 12 years of age the recommended interval between two doses of varicella is 12 weeks; this is also the minimum interval to be used when scheduling a second dose. However, if an interval as short as 4 weeks was used, the dose does not need to be repeated. For those ≥ 13 years of age the recommended interval between two doses of varicella is 6 weeks; this is also the minimum interval to be used when scheduling a second dose. However, if an interval as short as 4 weeks was used, the dose does not need to be repeated.
- ⑬ There is no minimum interval between a dose of Td and Tdap when Tdap is being given for pertussis protection.
- ⑭ The recommended interval between any meningococcal C conjugate vaccine and meningococcal quadrivalent conjugate vaccine is 4 weeks (regardless of which vaccine is given first).
- ⑮ SHINGRIX® is indicated for ages 50+ but only publicly funded for ages 65 and older starting Dec 6, 2021. Doses preferred to be given 2-6 months apart.

4.0 TIMING AND SPACING OF BIOLOGICAL PRODUCTS

Administration of all vaccines for which a person is eligible, at the same clinic visit, is critical to increasing the probability that a client will be fully vaccinated, and therefore, fully protected at the earliest opportunity.

Generally, adverse event profiles, immunogenicity, and parental compliance are similar to when vaccines are given at separate visits. Exceptions may apply, including giving multiple live attenuated vaccines to immune compromised individuals, see [Section 5-Immunization of Special Populations](#).

4.1 TIMING AND SPACING OF INACTIVATED VACCINES

Inactivated vaccines are **not** affected by the presence of circulating antibody and can therefore be administered before, after, or at the same time as a passive immunizing agent.

An inactivated vaccine can be administered concurrently or at any time before or after the administration of another inactivated vaccine or a live vaccine. The exceptions to this are the specific timing considerations between conjugate and polysaccharide presentations of the same antigen (e.g., PCV13 and PPV23 vaccines).

Inactivated vaccines almost always require multiple doses to generate lasting immunity. The first dose primes the immune system and a lasting protective immune response generally develops after one or more subsequent doses.

Immunity from many vaccines tends to wane over time, and for some inactivated vaccines may wane below protective levels, resulting in the need for periodic booster doses of the vaccine (e.g., tetanus/diphtheria toxoid vaccine).

Pure polysaccharide vaccines such as pneumococcal polysaccharide vaccine elicit a T-cell-independent response. As such, these vaccines are not usually effective in children under 2 years of age because they do not 'prime' the immune system, and repeat doses do not produce a sustained increase in antibody titres.

4.2 TIMING AND SPACING OF LIVE ATTENUATED VACCINES

Live attenuated vaccines must replicate in order to elicit an immune response. Agents that interfere with viral replication may affect the immune response. Examples include: interferon, antiviral medications, and circulating antibodies from maternal immunity or passive immunization. Issues related to the presence of circulating antibodies are discussed in [4.3 Spacing of Vaccines and Antibody-Containing Products](#).

In the first 14 days after the administration of a live attenuated vaccine, interferon is produced which would interfere with the immune response to another live vaccine when not administered concurrently. The interferon can prevent cells from becoming infected with the vaccine virus by killing the vaccine virus. For this reason, one live parenteral vaccine may interfere with the effectiveness of another if they are not given concurrently. They may also interfere with the effectiveness of intranasal vaccines, such as the live attenuated influenza vaccine (LAIV).

To minimize the possibility of vaccine interference, two or more live parenteral vaccines or a parenteral vaccine and the live attenuated influenza vaccine (LAIV) should be administered either on the same day or be separated by an interval of at least 28 days. The exception to this is the administration of varicella vaccine and another live vaccine to high risk/immunocompromised clients. For these clients, varicella vaccine should be administered 4 weeks apart from the administration of another live vaccine. Refer to [Section 5-Immunization of Special Populations](#).

If two live parenteral vaccines or a live parenteral vaccine and live intranasal influenza vaccine are not given on the same day and are given less than four weeks apart, the vaccine that was given second should be repeated 28 days after it was given.

Live vaccines given by the parenteral or intranasal route are not believed to have an effect on live vaccines given orally. Live oral vaccines can be given at any time before or after live vaccines administered parenterally or intranasally.

Antiviral medications also impact the ability of live attenuated vaccine viruses to replicate. For example, antivirals active against varicella zoster virus (VZV), such as acyclovir, famciclovir and valacyclovir, taken less than 2 days before or within 14 days after immunization may decrease vaccine effectiveness.

Live attenuated virus vaccines administered parenterally (e.g., MMR and varicella) usually produce prolonged immunity, even if antibody titres decline over time. Subsequent exposure to viruses usually does not lead to viremia but to a rapid anamnestic response.

For live attenuated parenteral vaccines, the first dose administered at the recommended age usually provides protection. A second dose is given to ensure seroconversion for those persons who fail to respond to the first dose.

4.3 SPACING OF VACCINES AND ANTIBODY-CONTAINING PRODUCTS

Live attenuated vaccines must replicate in order to elicit an immune response. For this reason, they are more sensitive to the presence of circulating antibody, including maternal antibodies and those present in passive immunizing agents. Circulating antibody against injected live vaccines can inhibit their ability to replicate, thereby inhibiting the immune response.

Antibody containing products include immune globulin (Ig) and blood products (e.g., whole blood, packed red blood cells, and plasma).

Ig preparations or blood products will not interfere with the antibody response when given simultaneously with, or at any interval before or after administration of any inactivated vaccine.

Ig preparations or blood products can interfere with the immune response to a measles, mumps, rubella or varicella-containing vaccine. For measles (routinely given as MMR or MMRV) and varicella vaccines, the recommended interval between Ig or blood product administration and subsequent vaccination varies, depending on the specific product and the dose given.

The length of time that interference with live parenteral vaccines occurs after administration of an antibody-containing product is directly related to the amount of antigen-specific antibody contained in the product. Live vaccines should be delayed until the antibody-containing product has degraded. For recommended intervals between antibody containing products and MMR or varicella vaccine administration, refer to the [Canadian Immunization Guide](#).

After immunization with parenteral or intranasal live attenuated virus vaccine, virus replication and stimulation of immunity occur in about 7 to 14 days. If the Ig preparation or blood product is given more than 14 days after parenteral or intranasal live attenuated virus vaccines, the immunization does not have to be repeated. If Ig or a blood product is administered less than 14 days post immunization with MMR or varicella vaccine, immunization should be repeated at an interval indicated in the [Canadian Immunization Guide](#).

There are no data to indicate Ig preparations interfere with the immune response to other live vaccines (e.g., yellow fever and typhoid). This is probably because Ig and blood products available in Canada are unlikely to contain substantial amounts of antibodies to these antigens.

Respiratory syncytial virus monoclonal antibody preparation (palivizumab--Synagis®) and washed red blood cells will not interfere with the immune response to any currently available live or inactivated vaccines.

Rh immune globulin (Rhlg) may theoretically interfere with the response to MMR and varicella vaccines. Women who receive Rhlg postpartum and are eligible for MMR and/or varicella vaccine should generally wait 3 months before being vaccinated with these vaccines. However, if there is a risk of exposure to measles, mumps, rubella, or varicella, a risk of pregnancy in the 3-month postpartum period, or a risk that vaccines may not be given later, MMR and/or varicella vaccines may be given prior to discharge with a second dose at the recommended interval if indicated. If MMR or varicella vaccine is given within 3 months of receipt of Rhlg, serologic testing for rubella or varicella should be done 3 months postpartum and at least 1 month after the final dose. Women who have not mounted an antibody response should be revaccinated.

4.4 SPACING OF VACCINES AND BLOOD DONATION

If an individual reports that they are planning to donate blood, inform them that there may be an interval recommended between vaccine receipt and blood donation. Information on deferral periods between vaccinations and blood donation can be found at [Canadian Blood Services](#).

4.5 VACCINATION FOLLOWING VACCINATION ADMINISTRATION ERRORS

Consult with the vaccine program before next dose given.

4.5.1 Vaccine or Antigen Given at Less Than the Minimum Interval

Consider a vaccine or vaccine-component dose given at less than the minimum interval to be an **invalid** dose and repeat the dose. The repeat dose should be spaced after the invalid dose by the recommended minimum interval (see also [4.5.3 Live Vaccines Given Less than 4 Weeks Apart](#)).

- If some of the components of a combination vaccine are valid, repeat only the component(s) that are invalid if the appropriate product is available (e.g., if only the hepatitis B component of an INFANRIX hexa® dose is invalid, repeat only the hepatitis B component using hepatitis B vaccine).
- Refer to [Minimum Intervals Between Vaccine Doses Table](#).

4.5.2 Vaccine Given at Less Than the Minimum Age

Consider a vaccine dose given at less than the minimum age to be an **invalid** dose and repeat the dose.

- Live vaccine (e.g., MMR or varicella): Repeat the dose when the child reaches the minimum age **and** at least 4 weeks after the dose that was given too early.
- Inactivated vaccine (e.g., INFANRIX hexa®): Repeat the dose when the child reaches the minimum age.

4.5.3 Live Vaccines Given Less Than 4 Weeks Apart

If two live vaccines are not given on the same day and are given less than four weeks apart, consider the vaccine that was given second to be **invalid**.

- Repeat the vaccine that was given second a minimum of 28 days after it was given.
- Exceptions to this are:
 - Rotavirus vaccine may be given any time before or after another live vaccine. The only scenario where this would occur, however, is MMR given between 6 months and less than or equal to 8 months of age for post-exposure prophylaxis or travel indications.
 - If LAIV is given less than 28 days after a live vaccine (such as MMR), and protection against influenza is required promptly, an injectable influenza vaccine should be administered.

4.5.4 Expired Vaccine

If an expired product is given inadvertently, the dose must be repeated.

- If it is a live vaccine, give on the same day the expired vaccine was given. If the error is discovered after that, repeat the dose of live vaccine 28 days later.
- If an expired dose of an inactivated product is given, give another dose as soon as possible.

4.6 Tuberculin Testing

Tuberculin skin tests can be administered at the same time, or at any time after most vaccines. However, live virus vaccines (e.g., MMR or varicella vaccine) may interfere with the test and produce a false negative response if the vaccine was given in the 4 weeks before the tuberculin skin test. If possible, delay the tuberculin skin test until at least 4 weeks following date of immunization with a live vaccine. If the test cannot be delayed, it is acceptable to do the test and discuss any negative results with Yukon Communicable Disease Control, TB Program. The test may have to be repeated or a chest X-Ray completed.

Live virus vaccines will not interfere with the tuberculin test if given on the same day as the test.

No data exist for the potential degree of tuberculin skin test suppression that might be associated with other live vaccines (e.g., yellow fever vaccine) but it would be prudent to follow the guidelines for MMR vaccine. An exception to this is rotavirus vaccine, the administration of which can occur at any time before or after a tuberculin skin test.

5.0 REFERENCES

Advisory Committee on Immunization Practices. General Recommendations on Immunization. Morbidity and Mortality Weekly Report. Recommendations and Reports. 2011; 60(2); 1-64. Available at:

<http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf>.

American Academy of Pediatrics. Red Book: Report of the Committee on Infectious Diseases. (29th ed.). Elk Grove Village, Illinois. 2012.

Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. 12th ed. Washington DC: Public Health Foundation, 2012. Available at: <http://www.cdc.gov/vaccines/pubs/pinkbook/index.html>.

Public Health Agency of Canada (PHAC). Canadian Immunization Guide. Ottawa, ON. Available at: <http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php>.